BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that the first patients have received doses of Brukinsa (zanubrutinib) through a charitable access initiative designed to provide the drug to patients in low- and middle-income countries (LMICs). This initiative is made possible by a partnership between BeiGene’s non-profit charitable foundation and The Max Foundation, a global health equity organization, which was established last year as part of Max’s Humanitarian Partnership for Access to Cancer Treatments (Humanitarian PACT).
Under this scheme, Brukinsa is now available to patients in Armenia and Nepal diagnosed with chronic lymphocytic leukemia (CLL). The program is set to last for three years and aims to extend access to a total of 29 LMICs, ensuring that all participating patients receive Brukinsa at no cost.- Flcube.com
